Vaccine Induced Seroreactivity Following Administration of ALVAC-HIV/AIDSVAX®B/E Identified by Common Anti-HIV Test Kits and Algorithms in Thailand
Issued Date
2025-10-01
Resource Type
eISSN
23288957
Scopus ID
2-s2.0-105017604742
Journal Title
Open Forum Infectious Diseases
Volume
12
Issue
10
Rights Holder(s)
SCOPUS
Bibliographic Citation
Open Forum Infectious Diseases Vol.12 No.10 (2025)
Suggested Citation
Akapirat S., Serti E., Pitisutthithum P., Nitayaphan S., Chariyalertsak S., Eamsila C., Panjapornsuk P., Kleebmontha A., Chantakulkij S., Tongchanakarn B., Savadsuk H., Dhitavat J., Gurunathan S., Sinangil F., Crowell T.A., Michael N.L., Robb M.L., Vasan S., O’Connell R.J. Vaccine Induced Seroreactivity Following Administration of ALVAC-HIV/AIDSVAX®B/E Identified by Common Anti-HIV Test Kits and Algorithms in Thailand. Open Forum Infectious Diseases Vol.12 No.10 (2025). doi:10.1093/ofid/ofaf578 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/112544
Title
Vaccine Induced Seroreactivity Following Administration of ALVAC-HIV/AIDSVAX®B/E Identified by Common Anti-HIV Test Kits and Algorithms in Thailand
Corresponding Author(s)
Other Contributor(s)
Abstract
Vaccine-induced seroreactivity (VISR) was evaluated in RV306 and was shown to vary markedly (0–32.5%) among 6 HIV diagnostic tests and 84 algorithms. Our data show that selecting the SD Bioline HIV-1/2 assay and algorithms which exclude the ImmunoComb®II Bispot and Alere™ Determine HIV-1/2 assays would almost eliminate VISR in RV306.